|
|
|
|
||
Patient numbersFirst, do no harm. Gene editing companies are highly intriguing. I have a small stake in SGMO. However, patient numbers treated are very small. Why is this important? Safety! Do you want to take a medication that alters your genome before long term safety can be established? If you have a debilitating disease, the answer certainly may be yes. If not, then there is often more careful consideration from patients and physicians (never mind the FDA). Epigenetics offers a different and exciting approach that is likely to get significant press and hype soon. What if a pill could cool down inflammatory proteins/complement etc and only have that affect on those in whom those pathways are activated? What if those pathways returned to activated after the medication was washed out of the system? No finality of treatment. Simply altering genetic transcription back to a baseline state. This approach offers huge possibilities in diseases with many causes....CAD/CKD/Dementia....not to mention inflammatory conditions and malignancies. RVX has now treated thousands of patients with Apabetalone and has seen continued safety signals. Some of these patients have been treated for almost three years. The Phase 3 readout is early next year on their cardiovascular study with important secondary endpoints of CKD and Dementia. Epigenetics hype is coming and RVX is a top candidate for continues share price appreciation as they move to the Nasdaq. Bfw |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
26930 | Re: Patient numbers | KillerNut | 0 | 11/16/2018 9:05:41 PM |